Paris, 20 March 2017, 8am
AB Science announces positive top-line results of final analysis from study
AB10015 of masitinib in amyotrophic lateral sclerosis (ALS), also known as Lou
Primary analysis is a success and confirms interim analysis
Company to host webcast on masitinib in ALS
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company
specializing in the research, development and commercialization of protein
kinase inhibitors (PKIs), today announced that the phase 2/3 study AB10015 of
masitinib in amyotrophic lateral sclerosis (ALS) has met its pre-specified
primary endpoint. This is the first successful phase 3 trial of a tyrosine
kinase inhibitor in the treatment of ALS, signifying masitinib as first-in-class
for ALS, with a unique mechanism of action against microglia cells.
A webcast will be hosted on 20 March 2017 at 6 pm (CET). To participate please
email at firstname.lastname@example.org.
Study AB10015 was a double-blind, placebo-controlled phase 2/3 study to compare
the efficacy and safety of masitinib in combination with riluzole, versus
placebo in combination with riluzole in the treatment of patients suffering from
In accordance with study protocol, the final analysis was performed based on
394 patients treated for 48-weeks and randomly allocated to three different
treatment arms: masitinib at 4.5 mg/kg/day, versus masitinib at 3 mg/kg/day,
versus placebo, each administered as an add-on to riluzole. The primary endpoint
was based on the change from baseline to week 48 in the revised Amyotrophic
Lateral Sclerosis Functional Rating Scale (ALSFRS-R). The ALSFRS-R score is a
validated rating instrument for monitoring the progression of disability in
patients with ALS, which correlates significantly with quality-of-life and
survival. This endpoint is recommended by EMA and FDA guidelines for
registration in ALS. Also consistent with EMA guidance, Progression Free
Survival (PFS) was included as a key secondary endpoint for registration, with
progression being defined as ALSFRS-R deterioration of more than 9 points or
death. A stepwise sequence of analysis was predefined to first test masitinib at
4.5 mg/kg/day versus placebo, and then masitinib at 3 mg/kg/day versus placebo.
For masitinib at 4.5 mg/kg/day:
* Primary analysis on the change in ALSFRS-R score at week 48 (mLOCF
methodology) is statistically significant with a P-value of 0.014.
* Sensitivity tests on the primary analysis consisted in two models to impute
a value at week 48 for any patients who discontinued treatment before week
48. Those sensitivity analyses are also significant with a P-value of 0.020.
* The key secondary analysis on PFS was statistically significant with a P-
value of 0.016.
* Quality-of-life measured by change in ALSAQ score was also statistically
significant with a P-value<0.01.
For masitinib at 3 mg/kg/day:
* There was a trend in favor of masitinib versus placebo for change in ALSFRS
score at week 48 (LOCF methodology) and likewise for the two imputation
models (sensitivity analyses) and in PFS (secondary analysis).
* The change in quality-of-life was statistically significant (p-value<0.01)
in favor of masitinib.
The adverse events observed for masitinib in study AB10015 were consistent with
its known safety profile. There were no new safety events at final analysis as
compared with interim analysis.
The final analysis confirms the interim analysis, which was performed with 50%
AB Science filed an application for marketing authorization of masitinib in ALS
at EMA in September 2016.
Full efficacy and safety data will be submitted for presentation at the European
Network for the Cure of ALS (ENCALS) annual meeting in Ljubljana, Slovenia (18 -
20 May, 2017).
Alain Moussy, CEO of AB Science said: "This is a very good news for the
patients. These final data confirm findings from the study's interim analysis
and proves that masitinib is capable of slowing down motoneuron degenerative
disease such as ALS, which is a devastating condition with an urgent unmet
Professor Olivier Hermine, President of AB Science scientific committee
declared: "Perhaps the most impressive finding from this study is that masitinib
has generated a significant difference in progression free survival with respect
to the placebo treatment-arm. Similar to cancer studies when PFS is
significantly improved, this indicates a clear clinical benefit in favor of
Dr. Jess Mora Pardina, international coordinator of study AB10015 and
neurologist expert in ALS declared: "Masitinib is one of the rare drugs
developed for the treatment of ALS that has proved its efficacy through
validated endpoints. These results are truly encouraging and can be considered
as a major breakthrough for ALS treatment, a condition that has proved extremely
challenging in the development of new effective medication. Masitinib may be the
long-awaited addition to the therapeutic armamentarium of ALS."
The mechanism of action of masitinib in ALS is based on the targeting of
neurotoxic aberrant glial cells via CSF1R inhibition, providing a
neuroprotective effect and slowing down neurodegeneration.
Amyotrophic lateral sclerosis is a rare degenerative disorder that results in
progressive wasting and paralysis of voluntary muscles. There are approximately
50,000 people with ALS in the European Union and in the US, with more than
16,000 new cases diagnosed each year in Europe and in the US. Almost 80% of ALS
patients die within 5 years and 90% die within 10 years.
Masitinib received orphan drug designation for ALS from both EMA and FDA.
Masitinib is a new orally administered tyrosine kinase inhibitor that targets
mast cells and macrophages, important cells for immunity, through inhibiting a
limited number of kinases. Based on its unique mechanism of action, masitinib
can be developed in a large number of conditions in oncology, in inflammatory
diseases, and in certain diseases of the central nervous system. In oncology due
to its immunotherapy effect, masitinib can have an effect on survival, alone or
in combination with chemotherapy. Through its activity on mast cells and
microglia and consequently the inhibition of the activation of the inflammatory
process, masitinib can have an effect on the symptoms associated with some
inflammatory and central nervous system diseases and the degeneration of these
About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the
research, development and commercialization of protein kinase inhibitors (PKIs),
a class of targeted proteins whose action are key in signaling pathways within
cells. Our programs target only diseases with high unmet medical needs, often
lethal with short term survival or rare or refractory to previous line of
treatment in cancers, inflammatory diseases, and central nervous system
diseases, both in humans and animal health.
AB Science has developed a proprietary portfolio of molecules and the Company's
lead compound, masitinib, has already been registered for veterinary medicine in
Europe and in the USA. The company is currently pursuing thirteen phase 3
studies in human medicine in metastatic prostate cancer, metastatic pancreatic
cancer, relapsing metastatic colorectal cancer, relapsing metastatic ovarian
cancer, GIST, metastatic melanoma expressing JM mutation of c-Kit, relapsing
multiple myeloma, relapsing T-cell lymphoma, mastocytosis, severe asthma,
amyotrophic lateral sclerosis, Alzheimer's disease and progressive forms of
multiple sclerosis. The company is headquartered in Paris, France, and listed on
Euronext Paris (ticker: AB).
Further information is available on AB Science's website: www.ab-science.com.
Forward-looking Statements - AB Science
This press release contains forward-looking statements. These statements are not
historical facts. These statements include projections and estimates as well as
the assumptions on which they are based, statements based on projects,
objectives, intentions and expectations regarding financial results, events,
operations, future services, product development and their potential or future
These forward-looking statements can often be identified by the words "expect",
"anticipate", "believe", "intend", "estimate" or "plan" as well as other similar
terms. While AB Science believes these forward-looking statements are
reasonable, investors are cautioned that these forward-looking statements are
subject to numerous risks and uncertainties that are difficult to predict and
generally beyond the control of AB Science and which may imply that results and
actual events significantly differ from those expressed, induced or anticipated
in the forward-looking information and statements. These risks and uncertainties
include the uncertainties related to product development of the Company which
may not be successful or to the marketing authorizations granted by competent
authorities or, more generally, any factors that may affect marketing capacity
of the products developed by AB Science, as well as those developed or
identified in the public documents filed by AB Science with the Autorit des
Marchs Financiers (AMF), including those listed in the Chapter 4 "Risk Factors"
of AB Science reference document filed with the AMF on November 22, 2016, under
the number R. 16-078. AB Science disclaims any obligationor undertaking to
update the forward-looking information and statements, subject to the applicable
regulations, in particular articles 223-1 et seq. of the AMF General
For additional information, please contact:
Financial Communication & Media Relations
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AB Science via GlobeNewswire